Cancer’s Vulnerability is Our Strength

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Learn More

Scientific Approach

Oncogenic transformations lead to DNA breaks that require repair for cancer cells to survive. This makes cancer cells vulnerable to targeted treatments that disrupt DNA damage response and repair. Cyteir treatments exploit this vulnerability by inducing synthetic lethality in tumor cells while sparing normal cells.

Learn More

Pipeline

Novel, best-in-class drugs targeting key cancer vulnerabilities

LEARN MORE

Patients

Enrollment is open in our Phase 1/2 trial for solid tumors and hematologic malignancies

LEARN MORE

Careers

At Cyteir, patients come first, science is key and collaboration is valued. Come join us!

LEARN MORE

Cyteir’s Culture

With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.​

Learn More

Recent News

“The development and approval of PARP inhibitors have paved the way for additional, novel DNA repair and synthetic lethality-based therapies to address unmet needs in cancer treatment.”

Markus Renschler, MD
President and Chief Executive Officer